Geron (GERN) is back in focus after its second quarter 2026 earnings release, fresh RYTELO revenue guidance for 2026 in the US$220 million to US$240 million range, and a new shelf registration filing.

At a latest share price of US$1.57, Geron has seen a 7 day share price return of 17.16% and a 90 day share price return of 12.95%, while the 1 year total shareholder return of 20.77% contrasts with a 3 year total shareholder return that is down 47.84%. This hints that recent earnings, RYTELO guidance and the shelf registration have shifted sentiment, but long term holders are still feeling earlier volatility.

If Geron’s recent move has your attention, this could be a good moment to widen your watchlist with other healthcare names and see what stands out in the 42 healthcare AI stocks.

Geron’s shares have jumped on RYTELO guidance and fresh earnings, yet the stock is still well below analyst targets and longer term holders are under water. Is most of the rerating still ahead or already priced in?

Most Popular Narrative: 53.8% Undervalued

Geron’s most followed narrative pegs fair value at $3.40, which is more than double the latest $1.57 close, so the current discount is hard to ignore for anyone tracking RYTELO’s launch and the broader pipeline story.

The expanding prevalence of hematologic diseases driven by an aging global population positions Geron for sustained revenue growth as the eligible patient pool for RYTELO and future indications increases, creating a long runway for top-line expansion.

Strong early adoption signals, combined with execution of expanded commercial and medical affairs teams, are driving increased brand awareness and deeper market penetration, likely to accelerate both new patient starts and duration of therapy, positively impacting revenue and operating leverage.

Want to see what sits behind that growth runway claim for Geron? The narrative focuses on aggressive revenue compounding, rising margins, and a future earnings profile that depends on much more than today’s single approved indication.

Result: Fair Value of $3.40 (UNDERVALUED)

However, the Geron narrative still hinges on RYTELO as a single key product, and on future capital raises that could dilute existing shareholders if funding needs remain high.

Next Steps

If this Geron story feels optimistic so far, now is the time to look through the numbers yourself and test that view against the detail. To see which potential rewards investors are focusing on, start with the 4 key rewards.

Looking for more investment ideas beyond Geron?

Do not let the story stop with Geron. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match the kind of portfolio you want to build.

• Target potential long term compounders by running through the 49 high quality undervalued stocks that filters for companies with quality fundamentals trading at a discount.
• Prioritise staying power in your holdings and search the solid balance sheet and fundamentals stocks screener (49 results) that focuses on companies with stronger financial footing.
• Get ahead of the crowd and review the screener containing 19 high quality undiscovered gems that highlights under the radar stocks with solid fundamentals before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.